$0.3907
-0.0197-4.8%
Last update: Nov 12, 2:14 AM
Caribou Biosciences Inc
CRBUNASDAQ
Caribou Biosciences fell 82.7% from $2.26 to $0.39, behind the S&P 500's +11.2%. Its worst day was Oct 7 (−45.6%), and its low came Nov 11 at $0.39.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.30 beat the $-0.36 estimate on $2.2M revenue (est. $2.1M).
−12.2% · S&P 500 −1.7%
EPS of $-0.28 beat the $-0.32 estimate on $3.9M revenue (est. $2.2M).
Story events cover the past 12 months · Times ET
+6.4% · S&P 500 −1.3%
EPS of $-0.26 beat the $-0.31 estimate on $2.4M revenue (est. $2.2M).
+3.2% · S&P 500 +0.8%
Caribou Biosciences closed at its highest level of the year, 7.5% above where the year started.
+3.0% · S&P 500 +0.3%
EPS of $-0.24 beat the $-0.31 estimate on $1.5M revenue (est. $2.3M).
−1.9% · S&P 500 −0.2%
Caribou Biosciences shares fell 45.6%, while the S&P 500 fell 0.2%.
−45.6%, the year's worst day, on 38M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $-0.25 beat the $-0.26 estimate on $1.6M revenue (est. $1.6M).
+8.8% · S&P 500 +0.3%
Where it ended: a close of $0.39 on Nov 11, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.27, revenue est. $20.4M).
Nothing in the past 12 months.
All CRBU dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CRBU and SPY from Benzinga historical bars. Not investment advice.
